Table 1. Main characteristics of study subjects with systemic lupus erythematosus.
| General Characterisitics | Patients (n = 45) |
| Age (yrs)1 | 42±13 |
| Female (%)2 | 88 |
| SLE characteristics | |
| Disease duration (yrs) | 13.3±8.6 |
| Age at SLE diagnosis (yrs) | 31.6±13.1 |
| SLE complications | |
| Arthrites (%) | 90 |
| Renal involvement (%) | 28 |
| Serositis (%) | 23 |
| Haematological manifestations (%) | 33 |
| Neurological manifestations (%) | 23 |
| Positive anti-dsDNA (ever) (%) | 83 |
| Antiphospholipid antibody (ever) (%) | 28 |
| Activity | |
| SLEDAI score | 4.4±3.6 |
| SDI score | 1.23±1.46 |
| Treatments | |
| Current use of prednisone (%)3 | 68 |
| Current use of HCQ (%) | 74 |
| Mean current prednisone dose (mg/day) | 3.6±3.1 |
| Mean current HCQ dose (mg/day) | 91±59 |
| Immunosuppressant agents (%) | 33 |
1
Age of Control group: n = 49, mean ± SD = 36.91 ±14 (19–61). No significant difference with SLE group (P-value> 0.05).
2
Female percentage of control group: 50%. No difference of ACSL5 levels between male and females of control group (see Figure 1B).
3
Prednisone treatment to patients affected ACSL5 transcript levels (see Figure 1C).